Insulin resistance in patients on valproic acid: Relation to adiponectin

Acta Neurologica Scandinavica

Volumn 131, Issue 3, 2015, Pages 169-175

  Aly, R H ^a   Amr, N H ^a   Saad, W E ^a   Megahed, A A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Adiponectin; Epilepsy; Insulin resistance; Valproic acid

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; VALPROIC ACID; ADIPOQ PROTEIN, HUMAN; ANTICONVULSIVE AGENT; GLUCOSE BLOOD LEVEL;

ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHILD; CHILDHOOD OBESITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; FEMALE; GENERALIZED EPILEPSY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MONOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; COMPLICATION; EPILEPSY, GENERALIZED; OBESITY; PHYSIOLOGY;

ADIPONECTIN; ADOLESCENT; ANTICONVULSANTS; BLOOD GLUCOSE; CHILD; EPILEPSY, GENERALIZED; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; VALPROIC ACID;

EID: 84938548367     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12313     Document Type: Article

References (44)

1. Meral C, Cekmez F, Vurucu S et al. New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid. Eur Cytokine Netw 2011;22:118-22.
2. Easter D, O'bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine - a reappraisal. Seizure 1997;6:121-5.
3. Luef G, Abraham I, Hoppichler F et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:1274-8.
4. Verrotti A, la Torre R, Trotta D, Mohn A, Chiarelli F. Valproate induced insulin resistance and obesity in children. Horm Res 2009;71:125-31.
5. Grosso S, Mostardini R, Piccini B, Balestri P. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother 2009;43:45-50.
6. Corman C, Leung N, Guberman A. Weight gain in epileptic patient during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24:240-4.
7. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514-7.
8. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
9. Chandran M, Phiillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442-50.
10. Korner A, Kratzsch J, Gausche R, Schaab M, Erbs S, Kiess W. New predictors of the metabolic syndrome in children - role of adipocytokines. Pediatr Res 2007;61:640-5.
11. Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 2005;65:1808-9.
12. Berg AT, Berkovic SF, Brodie MJ et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on classification and terminology, 2005-2009. Epilepsia 2010;51:676-85.
13. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240-3.
14. Duncan JS, Sander JW. The chalfont seizure severity scale. J Neurol Neurosurg Psychiatry 1991;54:873-6.
15. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-9.
16. Schwandt P, Kelishadi R, Ribeiro RQ, Haas GM, Poursafa P. A three-country study on the components of the metabolic syndrome in youths: the BIG Study. Int J Pediatr Obes 2010;5:334-41.
17. Schwandt P, Haas G-M. 2012 Waist circumference in children and adolescents from different ethnicities, childhood obesity, Dr. Sevil Ari Yuca (Ed.), ISBN: 978-953-51-0374-5, InTech, doi: 10.5772/17936. Available from: http://www.intechopen.com/books/childhood-obesity/waist-circumference-in-children-and-adolescents-from-different-ethnicities (Accessed 09/11/2013).
18. Atabek ME, Pirgon O. Assessment of insulin sensitivity from measurements in fasting state and during an oral glucose tolerance test in obese children. J Pediatr Endocrinol Metab 2007;20:187-95.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
20. Kortenhorst MS, Isharwal S, van Diest PJ et al. Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 2009;8:802-8.
21. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.
22. Jallon P, Picard F. Bodyweight and anticonvulsants: a comparative review. Drug Saf 2001;24:969-78.
23. Tokgoz H, Aydin K, Bulent O. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic patients treated with valproate. Childs Nerv Syst 2012;28:1049-53.
24. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-2.
25. Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006;8:643-8.
26. Aydin K, Serdaroglu A, Okuyaz C, Bideci A, Gucuyener K. Serum insulin, leptin, and neuropeptide Y levels in epileptic children treated with valproate. J Child Neurol 2005;20:848-51.
27. Sonmez FM, Zaman D, Aksoy A et al. The effects of topiramate and valproate on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy. Seizure 2013;22:856-61.
28. Kanemura H, Sano F, Maeda Y, Sugita K, Aihara M. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a Pathogenic mechanisms and open-label clinical trial of behavior therapy. Seizure 2012;21:496-500.
29. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002;80:696-702.
30. Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH. Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones 2009;41:20-4.
31. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-93.
32. Verotti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010;51:268-73.
33. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
34. Verrotti A, Basciani F, de Simone M, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:265-8.
35. Demir E, Ausun S. Weight gain associated with valproate in childhood. Pediatr Neurol 2000;22:361-4.
36. Luef G, Rauchenzauner M, Waldmann M et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009;86:42-7.
37. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003;52:1-8.
38. Breum L, Astrup A, Gram L et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metab, Clin Exp 1992;41:666-70.
39. Rauchenzauner M, Haberlandt E, Scholl-Burgi S et al. Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia 2008;49:353-7.
40. Tomoum H, El-Hadidi E. Ghrelin and resistin levels in children with epilepsy on valproic acid. J Pediatr Neurol 2009;7:223-9.
41. Valle M, Martos R, Gascon F, Canete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab 2005;31:55-63.
42. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI, Scott RS. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry 2009;43:53-60.
43. Qioa L, Maclean PS, Schaack J et al. C/EBP alpha regulates human adiponectin gene expression through an intronic enhancer. Diabetes 2005;54:1744-54.
44. Combs TP, Berg AH, Rajala MW et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003;52:268-76.